Donna Wilcock, Ph.D., of the University of Kentucky’s Sanders-Brown Center on Aging was awarded a $1.7 million National Institutes of Health grant for her lab’s exploration of adverse effects of two new Alzheimer’s disease drugs — aducanumab and lecanemab — which have been shown to slow the progression of cognitive decline.